Plasma RNA Viral Load in Human Immunodeficiency Virus Type 2 Subtype A and Subtype B Infections

Florence Damond, Marie Gueudin, Sophie Pueyo, Isabelle Farfara, David L. Robertson, Diane Descamps, Geneviève Chène, Sophie Matheron, Pauline Campa, Françoise Brun-Vézinet, and François Simon

Laboratoire de Virologie, INSERM U552, and Service des Maladies Infectieuses, SMIT A, Hôpital Bichat, 75877 Paris Cedex 18, Laboratoire de Virologie, Hôpital Charles Nicolle, 76031 Rouen, and INSERM U330, Bordeaux, France, and Zoology Department, Oxford University, Oxford, United Kingdom

Received 16 January 2002/Returned for modification 21 March 2002/Accepted 28 June 2002

Human immunodeficiency virus type 2 (HIV-2) is much less pathogenic than HIV-1, and HIV-2 infection is associated with plasma viral loads significantly lower than those found in HIV-1 infection. We have developed a real-time quantitative PCR method for measuring the HIV-2 RNA load that covers the range of genetic diversity of HIV-2 isolates and that detects extremely low viral loads. Samples from 49 patients were studied. Proviral DNA was first detected and quantified. The strains that were detected were then genotyped: 21 patients were infected with HIV-2 subtype A and 15 patients were infected with HIV-2 subtype B; 1 patient was infected with a highly divergent strain. Env PCR failed for the remaining 12 patients, so subtypes could not be determined. For viral RNA quantification, a stock of HIV-2 strain NIHZ, which was counted by electron microscopy, was used as the standard. Several primer sets targeting the highly conserved gag region were evaluated. Various primer combinations failed to amplify subtype B strains. With the final primer pair selected, which detected both subtype A and subtype B strains, the sensitivity of the assay was 100% at a viral load of 250 copies/ml and 66% at a viral load of 125 copies/ml. We found a correlation between the CD4+ -cell count, the clinical stage, and the plasma HIV-2 RNA level. The median plasma HIV-2 RNA value for the 33 asymptomatic patients was 2.14 log10, whereas it was 3.1 log10 for the 16 patients with AIDS (P < 0.01). Proviral DNA was detectable in 18 symptom-free patients with high CD4+ -cell counts, in whom viral RNA was undetectable.

Human immunodeficiency virus (HIV) type 2 (HIV-2) differs from HIV-1 by its lower pathogenicity and higher level of intrasubtype strain diversity. In addition, the incubation period for HIV-2 infection is longer, the time to progression to AIDS is slower (12), and the survival time with AIDS is longer (19). Similarly, the heterosexual and vertical transmission rates are lower with HIV-2 than with HIV-1. HIV-2 remains restricted to West Africa, where its prevalence is lower than that of HIV-1 (15–18). Thus, if HIV-2 is not less pathogenic, it is less virulent than HIV-1. No clear explanation for this difference has been found. The main hypothesis is that HIV-2 replication is less efficient than HIV-1 replication in vivo. This is based on the HIV-2 cellular load in quantitative culture and on a lower rate of plasma RNA positivity in vivo (4, 25). The first quantitative data on plasma HIV-2 RNA confirmed these differences in replication efficiency (23). In contrast, the HIV-2 proviral load is relatively high, with values similar to the HIV-1 proviral load (2).

The second major characteristic of HIV-2 is its high degree of genetic diversity (7, 8, 13, 21). The genetic distance between different HIV-2 subtypes is greater than that between the HIV-1 subtypes (9). It is thought that the HIV-2 subtypes identified so far correspond to separate cross-species transmission events between mangabeys (Cercocebus atys) and humans and thus are analogous to the HIV-1 groups, which are the result of separate cross-species transmission between chimpanzees (Pan troglodytes) and humans. Only HIV-2 subtype A and HIV-2 subtype B are prevalent and have been found outside West Africa (7, 8, 9, 13). The other subtypes (subtypes C to G) correspond to strains that are seemingly epidemiologically dead ends (7). This high level of genetic distance between the two major subtypes, subtypes A and B, makes it difficult to develop a single tool to detect their genomes. The extremely low viral load in most patients further hinders development of a quantitative assay for HIV-2 RNA in plasma. Real-time PCR provides a new approach to viral quantification. Its rapid execution permits large numbers of probes and primers to be tested. In the absence of a commercial PCR method for the follow-up of HIV-2-infected patients, we have developed a real-time PCR-based quantitative assay for HIV-2 RNA in plasma. This assay is not limited by the high degree of diversity of HIV-2 strains and permits a highly sensitive quantification of HIV-2 subtype A and subtype B.

MATERIALS AND METHODS

Patients and samples. We selected and tested 49 random plasma samples from patients living in France (24 men and 25 women). Most of the patients were of West African origin and were included in the French National Agency for AIDS Research HIV-2 national cohort. According to the Centers for Disease Control and Prevention (CDC) classification (6), 32 patients were at stage A, 1 patient was at stage B, and 16 patients were at stage C. Twenty-seven patients had CD4+ -cell counts above 300/μl; range, 302 to 1,161/μl; median, 529/μl; range, 302 to 1,161/μl; and 22 had values below 300/μl (mean ± SD, 118 ± 88/μl; median, 81/μl; range, 7 to 283/μl). Only seven patients had received antiretroviral treatment by the date of sampling: three had received long-term treatment (10 months to 6 years) with zidovudine, and the remaining

* Corresponding author. Mailing address: Laboratoire de Virologie, INSERM U552, Hôpital Bichat-Claude Bernard, 46 rue Henri Hu-chard, 75877 Paris Cedex 18, France. Phone: 00 33 1 40 25 88 96. Fax: 00 33 1 40 25 67 69. E-mail: florence.damond@bch.ap-hop-paris.fr.
four had received short-term treatment (less than 1 year) with a three-drug regimen.

HIV-2 infection was diagnosed by Western blotting (New Lav Blot II; Bio-Rad-Pasteur, Marnes la Coquette, France), and HIV-1 infection was ruled out by an HIV-1-specific enzyme-linked immunosorbent assay (Wellcozyme, HIV re-combinant; Murex Biotech Limited, Rungis, France). Plasma collected in tubes containing EDTA was centrifuged less than 3 h after sampling and stored at \(-80\)°C. Mononuclear cells were harvested on Ficoll (25), washed twice in phosphate-buffered saline, and stored as a dry pellet at \(-80\)°C.

**HIV-2 subtype determination.** The viral genotype was determined by nucleotide sequencing of the V3 loop and gp41 envelope region as described previously (11). Briefly, DNA was amplified by a first-round long (XL) PCR procedure with primers whose sequences are specific for sequences located in the pol and long terminal repeat regions. This was followed by nested PCR with primer pairs whose sequences correspond to the sequences of the V3 domain and the gp36 region of the HIV-2 env gene (9). The env sequences were compared to multiple env HIV-2 sequence alignments obtained from the Los Alamos National Laboratory HIV sequence database (http://hiv-web.lanl.gov) (20).

**Proviral DNA quantification.** Proviral DNA was quantified by a recently described real-time PCR method with primers whose sequences are specific for the sequence in the gag region. The real-time PCR method detects HIV-2 subtypes A and B (10). The linear range of our assay was 5 to 500,000 copies/10^7 peripheral blood mononuclear cells (PBMCs).

**Preparation of standards for RNA quantification.** A stock of HIV-2 strain NIH5, which was counted by electron microscopy, was used as the standard (Advanced Biotechnology Incorporated, Columbia, Md.). Prior to lysis, the stock solution contained 1.84 \( \times \) 10^9 virus particles/ml. The HIV-2 NIH5 stock solution was diluted in HIV-negative plasma to obtain 500,000, 50,000, 5,000, 500, and 250 copies in 140 \( \mu \)l. RNA was extracted with the Qiagen viral RNA minikit. Standards and samples were treated under the same conditions.

**PCR primers and hybridization probe for HIV-2 RNA.** In order to avoid major mismatches due to HIV-2 variability, the primers and probe were designed on the basis of published HIV-2 subtype A and B sequences (20). The sequence of the probe, designated S65GAG2, was 5'-R-TAGGTTACGGCCCGGAAAGA-Q-3' /H11032. The speciﬁc assay was 100%; all of HIV-2, the speciﬁc primers did not hybridize to HIV-1 genes. The speciﬁcity of our assay was 100%; all HIV-negative and HIV-1-positive plasma samples had values below 250 copies/ml. The sensitivity of the assay, based on repeated testing (6 replicates each) of the lower standard concentrations, was 100% at 250 and 500 copies/ml and 66% at 125 copies/ml. The quantification cutoff for the assay was thus set at 250 copies/ml.

**RESULTS**

**Primer selection.** PCR with primers F4 and R2 was negative for subtype B strains. The detection limit was unsatisfactory with primers F1, F2, F5, U3, and L140 (cutoff above 1,000 copies/ml) and/or these primers did not have the melting temperature required for reverse transcription (Fig. 1). The F3-R1 primer pair amplified all the strains with an adequate sensitivity and was selected for further development of the quantitative assay.

**Specificity, sensitivity, and reproducibility.** As expected because of the high degree of divergence between the HIV-1 and HIV-2 genomes, the HIV-2-specific primers did not hybridize to HIV-1 genes. The specificity of our assay was 100%; all HIV-negative and HIV-1-positive plasma samples had values below 250 copies/ml. The sensitivity of the assay, based on repeated testing (6 replicates each) of the lower standard concentrations, was 100% at 250 and 500 copies/ml and 66% at 125 copies/ml. The quantification cutoff for the assay was thus set at 250 copies/ml.

The LightCycler system offers good reproducibility for HIV-2 RNA quantification. For a theoretical virus concentration of 5.69 log_{10} copies/ml, we obtained a mean value of 5.67 log_{10} copies/ml with a within-run coefficient of variation of 1.78%. A mean copy number of 5.73 log_{10} copies/ml was obtained in repeat assays, with a between-run coefficient of variation of 1.04%. At the lowest concentration of 2.39 log_{10} copies/ml, we found mean values of 2.39 and 2.43 log_{10} copies/ml for within- and between-run assays, respectively, with coefficients of variation of 1 and 4.4%, respectively.

**HIV-2 subtype A and subtype B distribution in the patient population.** The env nucleotide sequences of the clinical HIV-2 isolates indicated that 21 patients were infected with HIV-2 subtype A and 15 were infected with HIV-2 subtype B; 1 patient, originating from the Ivory Coast, was infected with a highly divergent strain closely related to HIV-2 subtype C. We observed a slight but nonsignificant difference in CDC stages according to the infecting subtypes, with 11 subtype A-infected patients (52%) and 12 subtype B- and subtype C-infected patients (75%) being symptom-free (P < 0.20).

Amplification of the env gene was negative for 12 patients, all but 1 of whom had more than 310 CD4+ cells/\( \mu \)l, and 6 patients (50%) had proviral DNA levels below 5 copies/10^6 PBMCs. Amplification failed in a previously untreated patient with 25 CD4+ cells/\( \mu \)l, even in assays with primers whose sequences were specific for sequences located in other regions of the gene (9).

**The assay detects RNA of both HIV-2 subtypes.** The viral loads in samples from 22 of the 49 patients (45%) were above the detection limit of 250 copies/ml. Viral load values were between 250 and 500 copies/ml in seven patients, between 500 and 1,000 copies/ml in two patients, between 1,000 and 10,000 copies/ml in six patients, and above 10,000 copies/ml in seven patients. The frequency of plasma RNA positivity did not depend on the subtype, as 13 (62%) of the 21 patients with subtype A infection were positive, whereas 7 (43%) of the 16 patients with subtype B or “subtype C” infection were positive. However, the HIV-2 RNA viral load differed only slightly according to the subtype; the mean log_{10} values of the viral
FIG. 1. Positions of the sequences of the different primers and probes evaluated for use in the real-time PCR on the gag genes of two strains of HIV-2 subtype A (strains BEN and NIHZ) and one strain of HIV-2 subtype B (strain EHO).

**5' Primers**


- **1097 F1**: G T G G G A G A T G G G C G C G A G A

- **1099 U3**: G G G A G A T G G G C G C G A G A

**1106 F5**: G G G C G C G A G A A A C T C C G

- **1107 F4**: G G G C G C G A G A A A C T C C G T C T
- **1108 F3**: G C G C G A G A A A C T C C G T C T T G
- **1109 F2**: C G C G A G A A A A C T C C G T C T T G A G

**Probe**

- **NIHZ**: A A A A A A T T A G G T T A C G G C C C G G C G G A A A A A A A G

**3' Primers**


- **1196 R1**: A A C A T A T T G T G T G G C A G C G A A

- **1226 R2**: A C A G A T T C G G A T T G G C A G A G A G C

- **1234 L140**: G G A T T A G C A G A G A G C C T G T T G G A
The log₁₀ DNA value increased by 50% per 1 log₁₀ increment.

**Table 1.** Plasma RNA titers and proviral DNA values

<table>
<thead>
<tr>
<th>DNA viral load (no. of copies/ml)</th>
<th>No. of patients with the following DNA viral loads (no. of copies/10⁵ PBMCs):</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;250</td>
<td>9</td>
</tr>
<tr>
<td>250–1,000</td>
<td>12</td>
</tr>
<tr>
<td>1,000–10,000</td>
<td>5</td>
</tr>
<tr>
<td>&gt;10,000</td>
<td>1</td>
</tr>
<tr>
<td>Total</td>
<td>10</td>
</tr>
</tbody>
</table>

**DISCUSSION**

We have developed a real-time PCR method for quantification of the RNA of HIV-2 subtype A and subtype B strains in plasma. The detection limit is 250 copy equivalents/ml, and the reproducibility of the assay is satisfactory. The genetic diversity of HIV-2 was a major obstacle to the development of the assay, as HIV-2 subtypes A and B are more distant from each other phylogenetically than HIV-1 subtypes are to each other (9). One of the clinical isolates tested in the present study was closely related to HIV-2 subtype C, but more sequences are needed to establish its true phylogenetic position. The plasma RNA of this variant was detected by our real-time PCR method, showing that our assay encompasses the large range of genetic diversity of HIV-2 strains. Previous amplification-based methods for HIV-2 quantification have been assessed only locally, generally in West African countries, where only subtype A is prevalent (1, 2, 5, 14, 22), but they have also been assessed in Europe (24, 26). The strategy that we adopted ensures that both subtype A and subtype B strains are detected, as we targeted a conserved region in the central part of the gag gene for probe hybridization and then selected potential primers according to the position of the probe.

We observed a difference between subtype A and subtype B RNA levels in plasma that was not explained by antiretroviral treatments. This may have been due to a population bias, as the patients infected with subtype B, who mainly originated from the Ivory Coast, may have been infected more recently.

**FIG. 2.** Relation between plasma RNA viral load and CD4-cell counts. Points clustered at the bottom indicate undetectable HIV-2 viremia (limit of detection, 250 copies [cp/ml]). Log₁₀ RNA = 3.29 – 0.0019 × CD4 count (P < 10⁻⁴; r = −0.6275).

**FIG. 3.** Relation between plasma RNA and proviral DNA viral loads. Points clustered on the left indicate undetectable HIV-2 viremia (limit of detection, 250 copies [cp/ml]). Log₁₀ DNA = 0.349 + 0.533 × log₁₀ RNA (P < 0.0006; r = 0.473).
The keeping with the different rates of clinical progression (19), the HIV-2 viral load was lower than the HIV-1 viral load, in throughout the infection. Likewise, in our patients with AIDS, Popper et al. (23) observed a similar difference in a sex worker infection with HIV-2 than after primary infection with HIV-1. Reported that the set point was 28 times lower after primary-versely, values above 3.5 log_{10} were found exclusively in pa-

This is supported by the different distribution of clinical stages between patients infected with the two subtypes. Even if the RNA detection rate is the same for the two subtypes, less efficient amplification due to genomic diversity in subtype B cannot be ruled out. Indeed, only three HIV-2 subtype B gag sequences are available. An international effort is badly needed to sequence more HIV-2 strains.

The technique described here is the first technique to quantify subtype A and subtype B HIV-2 RNA by real-time PCR on the LightCycler system. The detection limit of 250 copies/ml is high, as half the samples tested had RNA at levels below this value. Others studies with different PCR systems have reported similar results, with cutoffs between 100 and 500 copies/ml and rates of positivity ranging between 56 and 62%. (3, 22, 24, 26).

### Table 2. Plasma RNA positivity and proviral DNA positivity according to clinical stage and CD4^+-cell counts^a^

<table>
<thead>
<tr>
<th>CDC stage</th>
<th>No. of CD4 cells/μl</th>
<th>RNA negative, DNA negative</th>
<th>RNA positive, DNA negative</th>
<th>RNA negative, DNA positive</th>
<th>RNA positive, DNA positive</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>&lt;300</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>10</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>≥300</td>
<td>1</td>
<td>0</td>
<td>3</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>A</td>
<td>&lt;300</td>
<td>2</td>
<td>0</td>
<td>1</td>
<td>8</td>
<td>11</td>
</tr>
<tr>
<td></td>
<td>≥300</td>
<td>6</td>
<td>0</td>
<td>13</td>
<td>3</td>
<td>22</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td>9</td>
<td>1</td>
<td>18</td>
<td>21</td>
<td>49</td>
</tr>
</tbody>
</table>

^a^ RNA positivity, >250 copies/ml; proviral DNA positivity, >5 copies/10^6^ PBMCs.

ACKNOWLEDGMENT

This work was supported by the French National Agency for AIDS Research.

REFERENCES

6. Centers for Disease Control. 1992. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adol-

This work was supported by the French National Agency for AIDS Research.


